Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia Dec 4, 2019
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients Nov 19, 2019
Moleculin Announces Beginning of Preclinical Development of New Approach to Pancreatic Cancer Nov 13, 2019
Moleculin Announces FDA Approval of IND for its STAT3 Inhibitor in Emory University Clinical Trial Nov 12, 2019
Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2019 Nov 12, 2019
Moleculin Announces New Data Confirms Anti-tumor Efficacy of Annamycin in Both Human and Murine AML Models Oct 29, 2019
Moleculin Increases Annamycin Production Due to Positive Clinical Trial Activity and Expanded Potential Indications Oct 22, 2019
Moleculin Announces its Sponsored Research at MD Anderson Cancer Center Has Resulted in the Filing of Patent Protection for New Discovery Sep 16, 2019
Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2019 Aug 16, 2019
